Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous theomboembolism after major orthopaedic surgery in Belgium

Acta Clinica Belgica

Volumn 59, Issue 6, 2004, Pages 346-357

  Annemans, L ^a,b   Minjoulat Rey, M C ^c   De Knock, M ^d   Vranckx, K ^d   Czarka, M ^d   Gabriel, S ^c   Haentjens, Patrick ^e  

^a GHENT UNIVERSITY   (Belgium)

^b Independent Research Organization   (Belgium)

^c SANOFI   (France)

^d Sanofi Synthelabo   (Belgium)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Belgium; Cost consequence analysis; Major orthopaedic surgery; Prevention of venous thromboembolism

Indexed keywords

ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMIC EVALUATION; EMBOLISM PREVENTION; HEALTH CARE COST; HIP FRACTURE; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MEDICAL FEE; ORTHOPEDIC SURGERY; RISK REDUCTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT INDICATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 15444377016     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hyers TM. Venous thromboembolism. Am J Respir Crit Care Med. 1999; 159: 1-14.
2. Agnelli G, Sonaglia F. Prevention of venous thromboembolism in high risk patients. Haematologica. 1997; 82: 496-502.
3. Marchetti, M. et al. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica. 1999; 84: 730-7.
4. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest. 2001; 119: 132S-175S.
5. Reverter JC. Fondaparinux Sodium. Drugs Today (Barc). 2002; 38: 185-94.
6. Diagnosis Related Group (DRG), Belgian Ministry of Health database, 1999.
7. Gordois A, Possnett J, Borris P, Jönsson B, Levy E and De Pouvourville G. The Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopaedic surgery. J Thromb Haemost. 2003; 1: 2167-74.
8. Bauer K.A. et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001; 345: 1305-10.
9. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial. Lancet. 2002; 359: 1721-6.
10. Lassen MR, Bauer KA, Eriksson BI, Turpie AGG, for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002; 359: 1715-20.
11. Eriksson BI, Bauer KA, Lassen MR, Turpie AG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001; 345: 1298-304.
12. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux versus enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of four randomized studies. Arch Intern Med. 2002; 162: 1833-40.
13. Ziegler S, Schillinger M, Maca TH, Minar E. Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. Thromb Res. 2001; 101: 23-33.
14. Caprini JA, Botteman MF, Stephens JM, Nadipelli V, Ewing MM, Brandt S, Pashos CL, Cohen AT. Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health. 2003; 6: 59-74.
15. Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopaedic surgery. JAMA. 1987; 257: 203-8.
16. Leclerc JR, Gent M, Hirsh J, et al. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin. Arch Intern Med. 1998; 158: 873-8.
17. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999; 81-A: 932-40.
18. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993; 329: 1370-6.
19. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo. Lancet. 1996; 348: 224-8.
20. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158: 1525-31.
21. Arixtra Public Assessment Report/Summary of Product Characteristics; First Published 15/04/02. The European Agency for the Evaluation of Medicinal Products.
22. Harrison, J. et al. Economics of thromboprophylaxis in total hip replacement surgery. Pharmacoeconomics. 1997; 12: 30-41.
23. Drummond, M et al. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg. 1994; 81: 1742-6.
24. Menzin, J et al. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: a pharmacoeconomic evaluation. Ann Pharmacother. 1994; 28: 271-5.
25. Menzin, J et al. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Int Med. 1995; 155: 757-64.
26. Bergqvist, D et al. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg. 1996; 83: 1548-52.
27. Hawkins, DW et al. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm. 1997; 54: 1185-90.
28. Hawkins, DW et al. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther. 1998; 20: 182-95.
29. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982; 306: 189-94.
30. Hull R, Hirsh J, Carter C, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982; 307: 1676-81.
31. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; 2: 515-8.
32. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost. 1994; 72: 191-7.
33. Das SK, Cohen AT, Edmonson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial. World J Surg. 1996; 20: 521-7.
34. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet. 1992; 339: 441-5.
35. Lopaciuk S, Bielska-Fada H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999; 81: 26-31.
36. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin®) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994; 71: 7-11.
37. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995; 332: 1661-5.
38. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: Incidence and risk factors. Arch Intern Med. 2000; 160: 769-74.
39. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996; 125: 1-7.
40. Ginsberg JS, Gent M, Turkstra T, et al. Postthrombotic syndrome after hip or knee arthroplasty: A cross-sectional study. Arch Intern Med. 2000; 160: 669-72.
41. Siragusa S, Beltrametti C, Barone M, Piovella F. Clinical course and incidence of post-phlebitic syndrome after asymptomatic deep vein thrombosis: Results of a cross-sectional epidemiological study. Minerva Cardioangiol. 1997; 45: 57-66.
42. Heit JA, Elliott CG, Trowbridge AA, et al. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement: A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000; 132: 853-61.
43. Pellegrini VD Jr, Clement D, Lush-Ehmann C, et al. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop. 1996; 333: 27-40.
44. Evans, C, Crawford E. Expert judgement in pharmacoeconomic studies. Guidance and future use. Pharmacoeconomics. 2000; 17: 545-53.
45. Répertoire commente des medicaments 2001; Centre belge d'information pharmacothérapeutique.: www.cbip.be (data used in the model were gathered in December 2001, when the current economic analysis was initiated).
46. Cogo A, Lensing AW, Prandoni P, Hirsh J. Distribution of Thrombosis in Patients with Symptomatic Deep Vein Thrombosis. Arch Intern Med. 1993; 153: 2777-80.
47. Lowe GDO, Sandercock PAG, Roosendal Fr. Prevention of venous thromboembolism after major orthopedic surgery: is fondaparinux an advance? Lancet. 2003; 362: 504-5.
48. Chevalier P. Fondaparinux in de preventie van thrombo-embolie na heupoperatie. Minerva. 2003; 2: 40-2.
49. Pourquoi récuser les critères combinés dans les essais cliniques du fondaparinux? La Revue Prescrire. 2003; 23: 396.
50. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001; 358: 9-15.
51. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001; 135: 858-69.
52. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery. Lancet. 2003; 362: 1582-3.
53. Turpie AG. The design of venous thromboembolism prophylaxis trials: Fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. Int J Clin Pract. 2004; 58: 483-93.
54. Lundkvist J, Bergqvist D and Jönsson B. Cost-effectiveness of fondaparinux vs enoxaparin as venous thromboembolism prophylaxis in Sweden. The European Journal of Health Economics. 2003; 4: 254-62.
55. Rieder A, Dorner Th, Kunze M, Reiter M, Nanz S. Kosteneffektivität von Fondaparinux versus Enoxaparin in der Prävention von venösen Thromboembolien nach größeren orthopädischen Eingriffen in Österreich. Perfusion 2004; 17: 1-8.
56. Haentjens P. and Annemans L. Review Article. Health economics and the orthopaedic surgeon. J Bone Joint Surg. (Br) 2003, 85-B: 1093-9.
57. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of health-care programmes. Second edition. New York: Oxford University Press, 1997: 3.